Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Pharmacotherapy|December 31, 2004
The role of oral direct thrombin inhibitors in the treatment of venous thromboembolismAnthony J Busti, Henry I BusseyPharmacotherapy|April 22, 2004
Tegaserod-induced myocardial infarction: case report and hypothesisAnthony J Busti, Jose R Murillo, Byron CryerPharmacotherapy|December 9, 2004
Atazanavir for the treatment of human immunodeficiency virus infectionAnthony J Busti, Ronald G Hall, David M MargolisPharmacotherapy|October 20, 2005
Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healingAnthony J Busti, Justin S Hooper, Christopher J Amaya, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|March 5, 2008
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavirAnthony J Busti, Roger Bedimo, David M Margolis, et al.Journal of Clinical Lipidology|February 5, 2011
A retrospective study of the lipid-lowering efficacy and safety of ezetimibe added to hydroxy methylglutaryl coenzyme A reductase therapy in HIV-infected patients with hyperlipidemiaLisa M Chastain, Amy M Bain, Krystal L Edwards, et al.Nature Clinical Practice. Nephrology|February 27, 2007
Evidence-based treatment recommendations for uremic bleedingStephanie J Hedges, Sarah B Dehoney, Justin S Hooper, et al.Pharmacotherapy|June 26, 2008
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literatureAmy M Bain, Elizabeth A White, William S Rutherford, et al.Journal of Cardiovascular Pharmacology|June 4, 2008
Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatinAnthony J Busti, Amy M Bain, Ronald G Hall, et al.Pharmacotherapy|June 26, 2008
Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapyAnita P Rahman, Susan A Eaton, Sean T Nguyen, et al.Pageof 2